Lundbeck to market Azilect in certain Asian countries
Danish pharmaceutical firm Lundbeck has won the rights to market Teva Pharmaceutical Industries" Azilect treatment for Parkinson\'s disease in six Asian countries.
Danish pharmaceutical firm Lundbeck has won the rights to market Teva Pharmaceutical Industries" Azilect treatment for Parkinson's disease in the six Asian countries of China, South Korea, Hong Kong, Malaysia, Thailand and the Philippines.
The company says Azilect will be a significant growth driver of its business in Asia, especially in China and South Korea. The agreement comes on top of the recent grant of reimbursement in China on Lundbeck's key products, Cipralex and Ebixa.
As part of the agreement Lundbeck will conduct clinical trials and prepare marketing authorisation applications in the individual markets. The first launch could take place in 12 months" time.
"The pharmaceutical markets in Asia, and the central nervous system (CNS) market in particular, is undergoing rapid development, and we see this agreement as a possibility to further strengthen our commercial platform in this promising region," said Ole Chrintz, senior vice president, commercial operations at Lundbeck.
Azilect is now available in 38 countries, including the US, Canada, Israel, Mexico and the EU. Lundbeck has the rights to market the drug in Europe (in collaboration with Teva in the UK, France and Germany) and in China, South Korea, Malaysia, Hong Kong, The Philippines, Thailand, and a few other countries outside Europe.
